Articles

By Vibhor Gupta, founder & CEO of Pangaea Data - As 2026 begins, the conversation around AI in healthcare feels markedly different from this time last year. Not because the technology itself has changed, but because expectations have. Across health systems, life sciences and R&D departments, there’s been a profound shift away from experimentation for its own sake towards accountable, transparent and reliable AI that demonstrates ROI within real care pathways, under real-world conditions.
As 2026 begins, the conversation around AI in healthcare feels markedly different from this time last year. Not because the technology itself has changed, but because expectations have. Across health systems, life sciences and R&D departments, there’s been a profound shift away from experimentation…

Aston University and Midlands-based company PFE Medical are teaming up to create biodegradable gloves made from food waste for use in the NHS.
Knowledge Transfer Partnership between Aston University and PFE Medical to develop a biodegradable clinical glove from food waste The gloves will provide a low-cost, convenient and sustainable alternative to the 1.4bn disposable gloves used in the NHS each year The innovation will reduce clinical waste and costs and help the NHS reach its net zero goals. Aston University and Midlands-based company PFE Medical are teaming up to create biodegradable gloves made from food waste for use in the NHS. They will offer a low-cost, convenient alternative to disposable gloves without compromising patient safety. More than 1.4bn disposable gloves are used by t…

Technology is changing how clinical trials are planned and carried out today simple digital tools help researchers collect data faster and reduce mistakes. Online systems also make it easier to track patient safety and study progress because of this trials can run more smoothly and reach results in less time while keeping patient care important.
The way we discover and test new medicines is undergoing a massive transformation for decades the process of bringing a life saving drug to the public was a slow, paper heavy journey that required patients to live near major city hospitals. However as we move further into 2026 technology has become the heartbeat of medical progress for anyone looking to start a career in this field, the first step is often enrolling in a clinical research course in…

Bioprinting is transforming pharma and biotech by enabling realistic human tissue models, accelerating drug discovery, and supporting personalised medicine. As adoption grows, it is creating new jobs across research, engineering, data science, quality, manufacturing, and commercial strategy.
Bioprinting is rapidly moving from research labs into commercial reality, and it is reshaping how the pharmaceutical and biotechnology industries think about drug development, regenerative medicine, and personalised healthcare. For professionals exploring future focused careers, bioprinting represents one of the most exciting intersections of biology, engineering, and digital innovation. Below, we explore what bioprinting is, why it is so important to pharma and biotech, and the key job roles it is expe…

Learn what a clinical trial protocol is, why it matters, and how it guides study design, compliance, and execution in clinical research.
A clinical trial protocol is the foundation of clinical research, detailing objectives, study design, eligibility, safety oversight, and data analysis. Its structure ensures consistency and credibility, guiding investigators while protecting participants and maintaining scientific rigor. With digital solutions, eProtocols and AI are modernizing protocols in clinical trials, making processes more adaptive and reducing inefficiencies. Introduction Every clinical trial depends on a detailed plan that outlines how the study will be run, how participants will be safeguarded, and how results will be measured. This plan, called a clini…

Living with IgA nephropathy (IgAN) often brings fears of kidney decline, persistent proteinuria, and eventual dialysis. Yet groundbreaking targeted therapies are bringing real hope, with Chinese-developed drugs like Telitacicept (a BLyS/APRIL inhibitor advancing through successful Phase 3 trials) and Iptacopan (an oral complement inhibitor approved in China in 2025 and globally) leading the charge. Alongside Nefecon® and atrasentan, these innovations attack root causes— from immune overproduction to complement activation and fibrosis—significantly reducing proteinuria, slowing eGFR loss, and potentially delaying end-stage disease. As markets expand and combination regimens emerge, IgAN is shifting from supportive care to personalized, reversible management, offering patients renewed energy and optimism.

Decentralized clinical trials software shifts research toward patient-centric models, blending remote tools with traditional rigor.
You're deep in clinical research operations, and decentralized clinical trials software has become the go-to for handling remote and hybrid models effectively. These clinical trials software fuses clinical research software capabilities with robust CTMS software to manage data flows, patient interactions, and compliance across distributed setups.   As the market surges toward USD 9.39 billion in 2025 with a 14.67% CAGR, these tools deliver the precision needed for faster, scalable trials.  Breaking Down Data Silos First  Start with unified platforms that integrate EDC, eCOA, and eConsent into a single system, so you avoid chasing data across vend…

Biodegradable thermal packaging is revolutionizing pharmaceutical shipping by delivering reliable temperature control with significantly reduced environmental impact. As demand for sustainable cold-chain logistics grows, these materials offer strong insulation, reduced waste and improved supply-chain efficiency. The industry still faces challenges like cost, scalability and regulatory alignment, but innovation is accelerating. Advances in biodegradable foams, compostable coolant packs and smart eco-sensors point to a future where sustainable, high-performance packaging becomes the global standard for transporting sensitive medications.
Biodegradable thermal packaging is revolutionizing the standards for transporting temperature-sensitive pharmaceuticals through global supply chains. As comp…

As digital mental health tools grow more sophisticated, UK regulators are drawing clearer lines between wellbeing support and medical devices. New MHRA guidance focuses on intended purpose and functional impact, helping developers understand when AI driven tools require medical device compliance.
Across the world, demand for mental-health support is exploding. Anxiety, depression, and sleep disorders are no longer fringe concerns but are headline issues, with health services struggling to keep up with the demand. Long waiting lists, staff shortages, and patchy access mean millions of people are left to cope alone. Into this gap has rushed a wave of Digital Mental Health Technologies (DMHTs) such as apps, platforms, and AI-powered tools promising fast, private, and tailored support. The gl…

Descubra las principales terapias antitumorales, los tipos de cáncer más relevantes y las estrategias modernas de tratamiento, con una visión de cómo las innovaciones en curso están dando forma al futuro de la oncología.
 El cáncer sigue siendo uno de los problemas de salud más importantes a nivel mundial, afectando a millones de personas cada año. Y su tratamiento a menudo conlleva dolor, sufrimiento e incertidumbre. Hoy, sin embargo, la oncología está siendo rápidamente transformada por la innovación tecnológica: desde inhibidores específicos hasta terapias celulares, y desde degradadores emergentes hasta anticuerpos biespecíficos. El campo de la oncología mundial está entrando en una “década dorada de terapias innovadoras”. Estos avances no sólo prolongan la vida de los pacientes, s…

European pharma is undergoing regulatory reform aimed at speeding access and balancing innovation with affordability. While new rules and incentives are emerging, major companies often view investment prospects outside Europe as more attractive, even as regional policy shifts seek to strengthen competitiveness.
Major regulatory overhaul in the EUThe European Union’s lawmakers have agreed a provisional pharma package to modernise medicine rules, speed up patient access, and boost competitiveness across the bloc. New provisions include defined periods of data and market protection for novel drugs and tools to improve supply security and antibiotic development. Some industry groups argue the measures still lag behind US incentives, potentially limiting Europe’s investment attractiveness. Reute…

2026 looks set to be a landmark year for therapeutics as late‑stage programs convert into global regulatory filings and commercial launches. Advances span neurology, immunology, cardiology, oncology, metabolic disease and rare genetic disorders, driven by targeted biologics, next‑generation cell and gene therapies, and improved small‑molecule and peptide agents. Expect broader access via biosimilars and formulation innovations (e.g., subcutaneous and oral versions), faster patient impact from accelerated pathways, and shifting treatment paradigms as pivotal trial successes translate into regionally staggered approvals and rapid market rollout.
Drug / Asset Developer Indication Expected region(s) Concise regulatory status Pivotal trial Oveporexton Takeda Narcolepsy (orexin‑2 agonist)…

A drug launch is the coordinated process of making a new therapy available after regulatory approval. It includes market access, medical education, commercial strategy, sales engagement, marketing, supply chain, safety monitoring, analytics, and patient support. Successful launches drive adoption and long term product impact.
A drug launch is one of the most defining events in the pharma and biotech lifecycle. It marks the moment a therapy moves from years of research and clinical testing into real world availability for patients. Launch success can determine whether a company grows, stalls, or even survives. Below is a clear,…

In 2026, NHS CIOs will shift focus from flashy AI tools to strategic, outcome-driven platforms that improve clinical care, streamline operations, and deliver measurable value.
AI continued to dominate the conversation in 2025, but in 2026, healthcare CIOs are shifting gears. After a year of rapid adoption and high expectations surrounding artificial intelligence, 2026 is shaping up to be the year CIOs apply a more strategic lens. Not to slow progress, but to steer it in a smarter direction. One that aligns with the NHS 10-Year Plan and delivers on integrated care ambitions. In 2025, we saw the rise of AI copilots across almost every platform imaginable as the world raced to embrace assistance-on-demand. But whil…

Independent survey exposes significant gaps in quality systems, supply chain oversight and data integration as EU GMP regulations tighten
OXFORD, UK, December 9, 2025 — Nearly one in four European pharmaceutical companies remains vulnerable to regulatory risks due to inadequate quality systems, according to new research from NSF, a leading global public health and safety organization.The independent study conducted by Opinium surveyed 100 senior regulatory and quality leaders across Europe and the UK. It found that 23% of companies operate with only basic compliance-level quality systems, exposing them to significant regulatory and operational risks as regulatory authority expectations increase.“European life sciences organizations are facing profound structural changes, from stricter regul…

The field of oncology is advancing rapidly with innovative anti-tumor therapeutics that enhance efficacy and reduce side effects through technologies like liposomes and albumin-bound formulations.
In the rapidly evolving field of oncology, the development of advanced anti-tumor therapeutics continues to offer new hope for patients battling various forms of cancer. As global healthcare systems grapple with rising cancer incidences, pharmaceutical innovations—particularly in targeted drug delivery systems like liposomes and albumin-bound formulations—are playing a pivotal role in improving treatment efficacy while minimizing side effects. This article explores key advancements in anti-tumor products, highlighting how these formulations are transforming cancer care and the importance of effici…

Digital first healthcare is transforming clinical trial engagement with AI, analytics, and personalised digital tools. Real time insights, adaptive education, and proactive communication strengthen retention, improve data quality, and build trust, helping sponsors deliver more efficient and patient centered trials.
The rise of digital-first healthcare is reshaping how clinical trial sponsors view patient engagement. Once focused primarily on regulatory compliance and data collection, patient engagement is now expanding to include features that improve the patient experience via communication and continuous support throughout the clinical journey. According to McKinsey, most healthcare consumers expect their interactions to be personalized and digitally enabled, implying that trial participa…

A collection of comments from life science and healthcare leaders regarding the UK's Autumn Budget.
The UK BioIndustry Association (BIA) welcomes key measures in today’s Autumn Budget that support the growth of life science and biotech scale-ups, while flagging concerns over rising costs for laboratory space. Commenting on the Chancellor's Autumn Budget 2025, Jane Wall, Managing Director of the UK BioIndustry Association (BIA), said: "BIA has long argued that outdated limits on venture investment tax incentives and employee share options are holding back the scale-up of life science companies, so we are delighted that the Chancellor has chosen to extend these today. Ahead of the Budget, the CEOs of 200 of our member companies wrote to the Chancellor calling for these changes, so we are pl…

As the biologics landscape accelerates toward increasingly complex, hybrid modalities, Syngene is positioning itself at the nexus of chemistry and biology. We sat down with Peter Bains, MD & CEO of Syngene International at CPHI Frankfurt, to discuss how the company is responding to this shift — from recent investments in peptide synthesis and ADC bioconjugation to the expanding expectations of CDMO partners, the growing role of automation, and India’s emergence as a global scientific force. In our conversation, Bains offers a clear view of how integrated capabilities, digital maturity, and cross-functional collaboration are shaping the next era of drug development.
 1) Syngene has made two significant investments recently — in peptide synthesis and ADC bioconjugation. What do these mov…